Rely on
Redmann

Louisiana’ premier
personal injury lawyer

scroll
Request Your Free Consultation

Ozempic/Semaglutide Class Action Lawsuit

As a groundbreaking innovation in medical treatment for Type 2 diabetes and weight management, semaglutide drugs like Ozempic have emerged as a significant development. These medications, recognized for their innovative approach to managing blood sugar levels and aiding in weight loss, have become a focal point in contemporary diabetes care. With the increasing prevalence of Type 2 diabetes and obesity-related health issues, understanding the role, efficacy, and risks associated with semaglutide drugs is important for both healthcare providers and patients. 

Although many patients have had success with using semaglutide drugs, others have suffered severe side effects leading to legal action against the drug manufacturers. 

Why Do Doctors Prescribe Semaglutide Drugs? 

Doctors prescribe semaglutide drugs like Ozempic primarily for their efficacy in managing Type 2 diabetes and, in some cases, for weight management. The reasons for their prescription include:

  • Blood Sugar Control: Semaglutide is effective in lowering blood sugar levels in adults with Type 2 diabetes. It works by enhancing insulin secretion and reducing glucagon production, leading to better glycemic control.
  • Weight Loss: Semaglutide has been found to reduce appetite and food intake, contributing to significant weight loss in many patients. This is particularly beneficial for individuals with Type 2 diabetes, as weight loss can improve glycemic control and reduce the risk of diabetes-related complications.
  • Cardiovascular Benefits: Studies have shown that semaglutide can provide cardiovascular benefits, reducing the risk of major adverse cardiovascular events such as heart attack and stroke in people with Type 2 diabetes and established cardiovascular disease.
  • Convenient Dosing: The once-weekly injection schedule of drugs like Ozempic offers more convenience compared to daily injections or medications, improving adherence to the treatment regimen.
  • Reduced Risk of Hypoglycemia: Compared to some other diabetes medications, semaglutide has a lower risk of causing hypoglycemia (low blood sugar), which is an important consideration in diabetes management.
  • Positive Impact on Other Health Parameters: Semaglutide can also positively affect other health markers, such as reducing blood pressure and aiding in the improvement of cholesterol levels.
  • Use in Weight Management: For individuals struggling with obesity or overweight, semaglutide (like Wegovy, specifically approved for this use) offers a treatment option that goes beyond traditional diet and exercise.

How Do Semaglutide Drugs Like Ozempic Work? 

Semaglutide drugs, including Ozempic, Wegovy, and Rybelsus, function by mimicking the effects of a naturally occurring hormone in the body known as glucagon-like peptide-1 (GLP-1). The mechanism of action for these medications involves several key aspects:

  • Enhancing Insulin Secretion: Semaglutide stimulates the pancreas to produce more insulin when blood sugar levels are high. Insulin is a hormone that helps cells absorb glucose (sugar) from the bloodstream, thus lowering blood sugar levels.
  • Reducing Glucagon Production: Alongside boosting insulin production, semaglutide helps lower the level of glucagon, another hormone produced by the pancreas. Glucagon typically increases blood sugar levels by signaling the liver to release stored glucose. By reducing glucagon, semaglutide aids in keeping blood sugar levels more stable.
  • Slowing Gastric Emptying: Semaglutide slows down the rate at which the stomach empties its contents into the small intestine. This slower digestion rate can lead to a feeling of fullness, reduced appetite, and consequently, a decrease in food intake. This aspect of semaglutide’s action is particularly relevant for its use in weight management.
  • Appetite Suppression: By affecting areas in the brain that regulate appetite, semaglutide can lead to reduced calorie intake due to decreased hunger and increased feelings of fullness.

These combined effects make semaglutide effective for managing Type 2 diabetes by improving blood sugar control and assisting in weight loss or weight management, which is a common challenge for individuals with Type 2 diabetes. 

Why are Semaglutide Drugs Like Ozempic Prescribed to Treat Obesity? 

The history of semaglutide drugs in the United States reflects significant advancements in the treatment of Type 2 diabetes and, more recently, in weight management. Semaglutide is a part of a class of drugs known as GLP-1 receptor agonists, which have played a crucial role in diabetes care. Here’s an overview of the key milestones:

    • Development of GLP-1 Agonists: The history begins with the understanding of the glucagon-like peptide-1 (GLP-1) hormone, which has a significant role in blood sugar regulation. Researchers identified the potential of GLP-1 to treat diabetes due to its ability to enhance insulin secretion and suppress glucagon release.
    • Introduction of Semaglutide: Semaglutide, developed by Novo Nordisk, a Danish multinational pharmaceutical company, was designed to have a longer duration of action compared to earlier GLP-1 receptor agonists. This allowed for less frequent dosing, making it more convenient for patients.
    • FDA Approval for Diabetes: Semaglutide was first approved by the U.S. Food and Drug Administration (FDA) under the brand name Ozempic in 2017 for the treatment of Type 2 diabetes. The approval was based on clinical trials showing its effectiveness in improving blood sugar levels and providing cardiovascular benefits.
    • Expanding to Weight Management: The efficacy of semaglutide in promoting weight loss was observed as a beneficial side effect in patients with Type 2 diabetes. This led to research and clinical trials focusing on its use as a weight management drug.
    • Approval for Weight Loss: In 2021, the FDA approved semaglutide for chronic weight management in adults under the brand name Wegovy. This approval marked a significant milestone as it was one of the few drugs shown to produce substantial weight loss in clinical trials, positioning it as a potential game-changer in obesity treatment.
    • Ongoing Research and Development: Research continues into the full potential and long-term effects of semaglutide. Studies are focusing on its cardiovascular benefits, effects on obesity-related comorbidities, and its long-term safety profile.
    • Emerging Concerns and Litigations: Alongside its success, there have been emerging concerns about the side effects and long-term safety of semaglutide, leading to legal actions and calls for more comprehensive patient information and monitoring.

What are the Side Effects of Semaglutide Drugs Like Ozempic? 

Semaglutide drugs such as Ozempic, Wegovy, and Rybelsus, while effective in managing Type 2 diabetes and aiding in weight loss, also carry potential risks and side effects. It is essential for patients and healthcare providers to be aware of these risks to make informed decisions about treatment. Key risks and side effects include:

  • Gastrointestinal Issues: Common side effects involve the gastrointestinal system, including nausea, diarrhea, vomiting, constipation, and abdominal pain. These symptoms can vary in intensity and duration.
  • Risk of Hypoglycemia: When used in combination with other diabetes medications, particularly those that increase insulin levels, there is an increased risk of hypoglycemia (low blood sugar). Symptoms of hypoglycemia include dizziness, sweating, confusion, and shakiness.
  • Pancreatitis: There have been reports linking semaglutide to an increased risk of pancreatitis, an inflammation of the pancreas, which can be a serious medical condition.
  • Gastroparesis: A condition known as gastroparesis, or delayed stomach emptying, can occur. This can lead to digestive problems and affect blood sugar management.
  • Gallbladder Issues: Use of semaglutide has been associated with gallbladder problems, including gallstones and inflammation of the gallbladder.
  • Risk of Thyroid C-cell Tumors: In animal studies, semaglutide has been linked to thyroid C-cell tumors. While it’s not clear if this applies to humans, it’s a potential risk, particularly for individuals with a personal or family history of thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
  • Allergic Reactions: As with any medication, there is a risk of allergic reactions, which can range from mild to severe.
  • Change in Heart Rate: Some individuals may experience an increased heart rate while taking semaglutide drugs.
  • Mental Health Effects: Mood changes and depression have been reported, although the direct connection to semaglutide is not fully established.
  • Kidney Problems: There have been cases where semaglutide has affected kidney function, including worsening of chronic kidney disease.
  • Effects During Pregnancy and Breastfeeding: The safety of semaglutide in pregnant or breastfeeding women is not well-established.

Semaglutide Drugs Lawsuit

A resident of Louisiana has initiated legal action against the manufacturers of Ozempic and Mounjaro, alleging that the companies have significantly understated the adverse effects of these widely used weight loss medications.

Jaclyn Bjorklund, aged 44, began using Ozempic in 2022 before transitioning to Mounjaro in July. According to the lawsuit, Bjorklund experienced intense gastrointestinal distress, including extreme vomiting and “gastrointestinal burning,” leading to multiple hospital and emergency room visits due to severe stomach pain.

Ozempic, also known as semaglutide, is a product of the Danish pharmaceutical firm Novo Nordisk. It received approval from the Food and Drug Administration in 2020 for treating insulin-dependent Type 2 diabetes.

Mounjaro, manufactured by Eli Lilly, is a comparable drug for Type 2 diabetes treatment and gained full FDA approval in May.

Both Ozempic and Mounjaro, administered through weekly injections, have become increasingly popular for their weight loss benefits, although their primary approval is for diabetes management.

Bjorklund’s lawsuit claims that she developed conditions such as gastroparesis, which involves delayed stomach emptying, and gastroenteritis, or the inflammation of the stomach lining.

Despite weight loss not being the primary objective of Ozempic or Mounjaro, it remains an integral component of long-term Type 2 diabetes management.

Novo Nordisk highlighted that semaglutide has been approved for over 15 years for Type 2 diabetes treatment, undergoing extensive evaluation in clinical development programs and real-world studies, with more than 9.5 million patient years of usage.

The company maintained that delayed gastric emptying, nausea, and vomiting are recognized side effects of the drug.  

While recent efforts on Capitol Hill have advocated for Medicare coverage of drugs like Ozempic and Wegovy, its counterpart for weight loss, as essential elements in obesity medicine, Novo Nordisk is facing scrutiny in Europe over a potential link between semaglutide and self-harmful thoughts.

The European Medicines Agency commenced an investigation into Ozempic in early July 2023 following reports of suicidal ideation in two patients after taking the drug. The Medicines and Healthcare products Regulatory Agency in the UK soon initiated a similar probe.

Considering these developments, individuals in Louisiana who have experienced adverse effects from semaglutide drugs such as Ozempic and Mounjaro are encouraged to seek legal guidance. The Law Office of John Redmann stands ready to assist. With a deep understanding of the complexities surrounding these cases, the team at Redmann Law is committed to providing comprehensive legal support. If experiencing injury or health complications due to semaglutide drugs, reach out to the Law Office of John Redmann for a consultation. Legal expertise can be a vital resource in navigating these challenging situations. Contact Redmann Law today for dedicated assistance in addressing any concerns or damages related to semaglutide drug use.